Non-invasive fetal sexing: medical test or a new tool for sex selection?

L. Osipenko, Ala Szczepura

Research output: Contribution to journalArticle

19 Downloads (Pure)

Abstract

Recent scientific developments in prenatal testing, based on fetal DNA in maternal blood, now allow non-invasive fetal sexing in pregnancies at risk of a sex-linked disorder. In such cases, these novel noninvasive tests can improve prenatal care by avoiding the need for invasive procedures such as amniocentesis, with their associated risk of fetal loss. The tests available for medical use are characterized by high levels of accuracy (> 99%) and early fetal sex determination (from week 7 of gestation). Many countries now offer families at risk of a sex-linked disorder this new form of clinical fetal sexing. At the same time, further developments in fetal DNA technology are making antenatal sex determination possible via a finger prick sample mailed anonymously to a commercial organization. Direct marketing to future parents of such non-invasive tests for social sex determination will bypass a woman’s physician. This could allow termination based on sex selection while women ostensibly present to physicians, who will have no access to the test result, for a termination on social grounds. If test results are available at 7 weeks gestation, online purchase of products for non-surgical abortion at home early in pregnancy could also enable some parents to bypass a health system altogether. Female feticide, linked to son preference and widespread ultrasound diffusion, has already led to significant gender imbalances in India and China. Certain ethnic minority communities in the west are also now displaying evidence of fetal sex selection. Currently, mail-order fetal sexing, based on fetal DNA in maternal blood, is still an emerging market. However, before any widespread diffusion, discussion about the implications of this new technology and associated issues is important and timely. This article considers evidence of technology development, existing demographic and social changes, corporate responsibility in product marketing, and the role of community engagement and education.
Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalDiversity & Equality in Health and Care
Volume8
Issue number1
Publication statusPublished - 12 Oct 2010

Fingerprint

Sex Preselection
Physiological Sexual Dysfunctions
Pregnancy
Marketing
DNA
Parents
Mothers
Women Physicians
pregnancy
Technology
parents
direct marketing
Amniocentesis
Prenatal Care
physician
Postal Service
Fetal Development
Social Change
Nuclear Family
Fingers

Bibliographical note

Full text available from: http://diversityhealthcare.imedpub.com/noninvasive-fetal-sexing-medical-test-or-a-new-tool-for-sex-selection.php?aid=1911

Keywords

  • fetal sex determination
  • gender imbalance
  • non-invasive diagnosis
  • prenatal testing
  • sex selection
  • son preference

Cite this

Non-invasive fetal sexing: medical test or a new tool for sex selection? / Osipenko, L.; Szczepura, Ala.

In: Diversity & Equality in Health and Care, Vol. 8, No. 1, 12.10.2010, p. 37-44.

Research output: Contribution to journalArticle

@article{4b2b1e02303d4c0a934a23a956bd3ab2,
title = "Non-invasive fetal sexing: medical test or a new tool for sex selection?",
abstract = "Recent scientific developments in prenatal testing, based on fetal DNA in maternal blood, now allow non-invasive fetal sexing in pregnancies at risk of a sex-linked disorder. In such cases, these novel noninvasive tests can improve prenatal care by avoiding the need for invasive procedures such as amniocentesis, with their associated risk of fetal loss. The tests available for medical use are characterized by high levels of accuracy (> 99{\%}) and early fetal sex determination (from week 7 of gestation). Many countries now offer families at risk of a sex-linked disorder this new form of clinical fetal sexing. At the same time, further developments in fetal DNA technology are making antenatal sex determination possible via a finger prick sample mailed anonymously to a commercial organization. Direct marketing to future parents of such non-invasive tests for social sex determination will bypass a woman’s physician. This could allow termination based on sex selection while women ostensibly present to physicians, who will have no access to the test result, for a termination on social grounds. If test results are available at 7 weeks gestation, online purchase of products for non-surgical abortion at home early in pregnancy could also enable some parents to bypass a health system altogether. Female feticide, linked to son preference and widespread ultrasound diffusion, has already led to significant gender imbalances in India and China. Certain ethnic minority communities in the west are also now displaying evidence of fetal sex selection. Currently, mail-order fetal sexing, based on fetal DNA in maternal blood, is still an emerging market. However, before any widespread diffusion, discussion about the implications of this new technology and associated issues is important and timely. This article considers evidence of technology development, existing demographic and social changes, corporate responsibility in product marketing, and the role of community engagement and education.",
keywords = "fetal sex determination, gender imbalance, non-invasive diagnosis, prenatal testing, sex selection, son preference",
author = "L. Osipenko and Ala Szczepura",
note = "Full text available from: http://diversityhealthcare.imedpub.com/noninvasive-fetal-sexing-medical-test-or-a-new-tool-for-sex-selection.php?aid=1911",
year = "2010",
month = "10",
day = "12",
language = "English",
volume = "8",
pages = "37--44",
journal = "Diversity & Equality in Health and Care",
issn = "2049-5471",
publisher = "Radcliffe Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - Non-invasive fetal sexing: medical test or a new tool for sex selection?

AU - Osipenko, L.

AU - Szczepura, Ala

N1 - Full text available from: http://diversityhealthcare.imedpub.com/noninvasive-fetal-sexing-medical-test-or-a-new-tool-for-sex-selection.php?aid=1911

PY - 2010/10/12

Y1 - 2010/10/12

N2 - Recent scientific developments in prenatal testing, based on fetal DNA in maternal blood, now allow non-invasive fetal sexing in pregnancies at risk of a sex-linked disorder. In such cases, these novel noninvasive tests can improve prenatal care by avoiding the need for invasive procedures such as amniocentesis, with their associated risk of fetal loss. The tests available for medical use are characterized by high levels of accuracy (> 99%) and early fetal sex determination (from week 7 of gestation). Many countries now offer families at risk of a sex-linked disorder this new form of clinical fetal sexing. At the same time, further developments in fetal DNA technology are making antenatal sex determination possible via a finger prick sample mailed anonymously to a commercial organization. Direct marketing to future parents of such non-invasive tests for social sex determination will bypass a woman’s physician. This could allow termination based on sex selection while women ostensibly present to physicians, who will have no access to the test result, for a termination on social grounds. If test results are available at 7 weeks gestation, online purchase of products for non-surgical abortion at home early in pregnancy could also enable some parents to bypass a health system altogether. Female feticide, linked to son preference and widespread ultrasound diffusion, has already led to significant gender imbalances in India and China. Certain ethnic minority communities in the west are also now displaying evidence of fetal sex selection. Currently, mail-order fetal sexing, based on fetal DNA in maternal blood, is still an emerging market. However, before any widespread diffusion, discussion about the implications of this new technology and associated issues is important and timely. This article considers evidence of technology development, existing demographic and social changes, corporate responsibility in product marketing, and the role of community engagement and education.

AB - Recent scientific developments in prenatal testing, based on fetal DNA in maternal blood, now allow non-invasive fetal sexing in pregnancies at risk of a sex-linked disorder. In such cases, these novel noninvasive tests can improve prenatal care by avoiding the need for invasive procedures such as amniocentesis, with their associated risk of fetal loss. The tests available for medical use are characterized by high levels of accuracy (> 99%) and early fetal sex determination (from week 7 of gestation). Many countries now offer families at risk of a sex-linked disorder this new form of clinical fetal sexing. At the same time, further developments in fetal DNA technology are making antenatal sex determination possible via a finger prick sample mailed anonymously to a commercial organization. Direct marketing to future parents of such non-invasive tests for social sex determination will bypass a woman’s physician. This could allow termination based on sex selection while women ostensibly present to physicians, who will have no access to the test result, for a termination on social grounds. If test results are available at 7 weeks gestation, online purchase of products for non-surgical abortion at home early in pregnancy could also enable some parents to bypass a health system altogether. Female feticide, linked to son preference and widespread ultrasound diffusion, has already led to significant gender imbalances in India and China. Certain ethnic minority communities in the west are also now displaying evidence of fetal sex selection. Currently, mail-order fetal sexing, based on fetal DNA in maternal blood, is still an emerging market. However, before any widespread diffusion, discussion about the implications of this new technology and associated issues is important and timely. This article considers evidence of technology development, existing demographic and social changes, corporate responsibility in product marketing, and the role of community engagement and education.

KW - fetal sex determination

KW - gender imbalance

KW - non-invasive diagnosis

KW - prenatal testing

KW - sex selection

KW - son preference

M3 - Article

VL - 8

SP - 37

EP - 44

JO - Diversity & Equality in Health and Care

JF - Diversity & Equality in Health and Care

SN - 2049-5471

IS - 1

ER -